Metraipolis › archive › dc_219c5e5df285

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41406177
DOI
10.1371/journal.pmed.1004651
License (as archived)
solo-consultazione
Archived
2026-11-07T13:58:09.804Z
SHA-256 of the archived text
d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa
Stable URL of this page
https://metraipolis.com/documento/dc_219c5e5df285

How to cite

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177 — Europe PMC (en), https://europepmc.org/article/MED/41406177 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_219c5e5df285 (Metraipolis archive dc_219c5e5df285, sha256 d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa)
BibTeX
@misc{dc219c5e5df285,
  title = {Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41406177},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_219c5e5df285; sha256 d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41406177. Agents can read the archived copy with the MCP tool read_document.